,10,11,12 However, despite the well-reported evidence of CD13 over-expression and activity in cancer progression, the ubiquitous nature of its expression in normal tissues as generally reported remains a limitation to the full potential clinical utility of CD13 as a target for cancer therapeutics and drug discovery being exploited.9 This evidence concerns the gene ANPEP and cancer.